Brief: DAWNZERA Receives Positive Opinion From CHMP, Recommended For Approval In EU For Hereditary Angioedema
14/11/2025 12:01
Nov 14 (Reuters) - Ionis Pharmaceuticals Inc IONS.O: DAWNZERA™(DONIDALORSEN) RECEIVES POSITIVE OPINION FROM CHMP, RECOMMENDED FOR APPROVAL IN EU FOR HEREDITARY ANGIOEDEMA (HAE) IONIS PHARMACEUTICALS INC - EUROPEAN COMMISSION DECISION EXPECTED IN Q1 2026 Source text: ID:nBwbmWzh1a Further company coverage: IONS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ionis Pharmaceuticals
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
Focus: AI companies run virtual drug trials, aim to improve success of human studies
Brief: Ionis Pharmaceuticals Says Ulefnersen Demonstrates Favorable Safety And Tolerability Profile
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study